People: Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

62.32USD
4:00pm EDT
Price Change (% chg)

$0.29 (+0.47%)
Prev Close
$62.03
Open
$62.01
Day's High
$62.80
Day's Low
$61.90
Volume
890,070
Avg. Vol
1,039,765
52-wk High
$65.65
52-wk Low
$47.53

Search Stocks

Summary

Name Age Since Current Position

John Lechleiter

61 2013 Chairman of the Board, President, Chief Executive Officer

Derica Rice

49 2013 Chief Financial Officer, Executive Vice President - Global Services

Maria Crowe

54 2012 President - Manufacturing Operations

Jan Lundberg

60 2010 Executive Vice President - Science and Technology, President - Lilly Research Laboratories

Melissa Barnes

45 2013 Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Michael Harrington

51 2013 Senior Vice President, General Counsel

Stephen Fry

48 2011 Senior Vice President - Human Resources and Diversity

Enrique Conterno

47 2009 Senior Vice President and President - Lilly Diabetes

Susan Mahony

49 2011 Senior Vice President and President - Lilly Oncology

Barton Peterson

55 2009 Senior Vice President - Corporate Affairs and Communications

David Ricks

46 2012 Senior Vice President, President - Lilly Bio-Medicines

Jeffrey Simmons

46 2008 Senior Vice President and President - Elanco Animal Health

Fionnuala Walsh

54 2011 Senior Vice President - Global Quality

Alfonso Zulueta

51 2014 Senior Vice President and President - Emerging Markets business

Ellen Marram

67 2013 Lead Independent Director

Ralph Alvarez

58 2009 Independent Director

Katherine Baicker

42 2011 Independent Director

Winfried Bischoff

2000 Independent Director

Michael Eskew

65 2008 Independent Director

J. Erik Fyrwald

54 2005 Independent Director

Alfred Gilman

72 1995 Independent Director

R. David Hoover

68 2009 Independent Director

Karen Horn

70 2012 Independent Director

William Kaelin

56 2012 Independent Director

Douglas Oberhelman

61 2008 Independent Director

Franklyn Prendergast

69 1995 Independent Director

Marschall Runge

59 2013 Independent Director

Kathi Seifert

64 1995 Independent Director

Jackson Tai

63 2013 Independent Director

Biographies

Name Description

John Lechleiter

Dr. John C. Lechleiter, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Eli Lilly And Co. He was appointed president and chief executive officer of Lilly since April 1, 2008. He became the chairman of the board of directors on January 1, 2009. He began work at Lilly in 1979 as a senior organic chemist in process research and development. Prior to joining Lilly, Dr. Lechleiter attended Xavier University (Cincinnati, Ohio), where he earned a bachelor of science degree in chemistry in 1975, and Harvard University, where he earned master's and doctoral degrees in organic chemistry in 1980. Dr. Lechleiter has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, and the National University of Ireland. Dr. Lechleiter is a member of the American Chemical Society and Business Roundtable. Dr. Lechleiter serves as chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), as president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and on the boards of United Way Worldwide, Xavier University, the Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the board of Nike, Inc.

Derica Rice

Mr. Derica W. Rice is Chief Financial Officer, Executive Vice President - Global Services of Eli Lilly and Co. He served as Acting Chief Executive Officer of the Company from May 13, 2013 to July 8, 2013. He has been appointed as Chief Financial Officer since May 2006 & Executive Vice President - Global Services of the Company since January 2010. He joined the company in 1990 as an international treasury associate. He has held leadership roles during his tenure, including chief financial officer for Lilly Canada, executive director and chief financial officer for European operations based in London, and the general manager of Lilly United Kingdom and Republic of Ireland. Prior to becoming Lilly's CFO in 2006, Rice had been the vice president and controller since July 2003. Mr. Rice received a bachelor's degree in electrical engineering from Kettering University (formerly the GMI Engineering & Management Institute) in 1988 and a master's degree in business administration in 1990 from Indiana University. In 2009, Rice was selected as one of the "Most Powerful Executives in Corporate America" by Black Enterprise magazine and he was selected as one of Diversity MBA magazine's "Top 100 Under 50 Executives." He serves as a member of the board of directors for Target Corporation, Clarian Health North and The Center for Leadership Development. He serves as a member of the Indiana University Board of Trustees and the Board of Governors of the Indianapolis Museum of Art.

Maria Crowe

Ms. Maria A. Crowe is President - Manufacturing Operations of Eli Lilly and Co. She was senior vice president for global drug product manufacturing of the company. She was general manager of manufacturing sites in Ireland and Puerto Rico. As head of manufacturing operations, she will lead a network of 22 sites in 13 countries and also will have responsibility for Lilly's global contract-manufacturing organization. She has served as senior vice president for global drug product manufacturing since August 2009. In this role, she has overseen all of Lilly's drug product manufacturing, packaging, and distribution operations. In her 29-year Lilly career, she has held roles in drug product and active pharmaceutical ingredient (API) manufacturing, as well as in sourcing and procurement. Prior to her current role, she was vice president for drug product manufacturing in the Americas ( the United States and Latin America). She served as general manager at Lilly's Kinsale, Ireland, plant; general manager of Lilly del Caribe in Puerto Rico; and plant manager of Lilly's Elanco manufacturing plant at the former Tippecanoe manufacturing site. She holds a bachelor's degree in industrial management from Purdue University.

Jan Lundberg

Dr. Jan M. Lundberg Ph.D., is Executive Vice President - Science and Technology, President - Lilly Research Laboratories of Eli Lilly and Co. He has a Ph.D. from Sweden's Karolinska Institute, where he was a professor in the department of pharmacology before moving to industry. Prior to Karolinska, he attended Gustavus Adolphus College in Minnesota and the University of Gothenburg in Sweden. He has been a member of the Swedish Medical Research Council and of the Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala University. During the last 10 years at AstraZeneca, as head of global discovery research, he was instrumental in delivering 150 drug candidates to the company's pipeline. He had a role in external activities, including in-licensing of projects and technologies, as well as acquisitions of biotech companies. His organization was with both small molecules and biologics. For the past seven years, he has been an executive vice president and member of the senior executive team, reporting to the CEO of AstraZeneca.

Melissa Barnes

Michael Harrington

Stephen Fry

Mr. Stephen F. Fry is Senior Vice President - Human Resources and Diversity of Eli Lilly and Co. He was the managing director of Lilly's Australian affiliate from 2004 -- 2007, then served in human resources capacities as executive director for the intercontinental region and Japan until becoming vice president for bio-medicines and emerging markets. He joined Lilly in 1987 as a scientific systems analyst in the company's former Greenfield, Ind. laboratories, moving into human resources in 1992. He assumed a leadership role when he was selected as the director of human resources for Lilly's United Kingdom affiliate in 1998, followed by executive director positions for both Lilly's U.S. affiliate and the pharmaceutical operations area. He has a bachelor's degree in business from the University of Indianapolis.

Enrique Conterno

Mr. Enrique A. Conterno is Senior Vice President and President - Lilly Diabetes of Eli Lilly & Co. Mr. Conterno became president of the diabetes business unit on November 1, 2009. The business unit, which becomes operational on January 1, 2010, enhances the company’s diabetes focus. Since January 2009, he had served as president of Lilly USA. He is a member of Lilly's operations committee and senior management council. He earned a master's of business administration degree at Duke University in 1992. He earned his bachelor’s degree in mechanical engineering from Case Western Reserve University in 1989. He joined Lilly as a sales representative in 1992. From 1993 to 1995, he held as a financial analyst, marketing associate, and business development manager. In 1996, Conterno became sales and marketing director for the Peru affiliate, and in 1998, he became the sales and marketing director for Lilly's affiliate in Brazil. In 2000, he was named executive director of marketing for the intercontinental region and Japan. He served as president and general manager for Lilly’s operations in Mexico in 2003, and was named vice president of Lilly USA's neuroscience business unit in July 2006. In June 2008, he was named senior vice president of health care professional markets for Lilly USA.

Susan Mahony

Dr. Susan Mahony Ph.D., is Senior Vice President and President - Lilly Oncology of Eli Lilly and Co. She has been Senior Vice President, Human Resources and Diversity (May 2009 – February 2011). Ms. Mahony joined Lilly eight years ago, after a decade in sales and marketing roles in the United Kingdom and Europe for Amgen, Bristol-Myers Squibb, and Schering-Plough. She was named general manager of Lilly Canada in 2008 after roles in global marketing and new product development, including a leadership in the development of Cymbalta(R). She was the Six Sigma leader for Lilly's sales and marketing component. Ms. Mahony received her bachelor's degree and Ph. D. in pharmacy from Aston University in Great Britain, and holds an MBA from the London Business School.

Barton Peterson

Mr. Barton R. Peterson is Senior Vice President - Corporate Affairs and Communications of Eli Lilly and Co. Mr. Peterson served as mayor of Indianapolis, Indiana from 2000 to 2007. From 2008 to 2009, he was managing director at Strategic Capital Partners, LLC, and distinguished visiting professor of public policy at Ball State University.

David Ricks

Mr. David A. Ricks is Senior Vice President, President - Lilly Bio-Medicines of Eli Lilly and Co. He formerly was general manager of Lilly affiliates in China and Canada. Ricks' responsibilities will include the U.S., Japan, and Europe. Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal, and urology. He is a 15-year Lilly veteran, has led three of Lilly's important affiliates: the U.S., China, and Canada. As president of Lilly USA since 2009, Ricks spearheaded a new operating model focused on customer satisfaction and revenue growth while preparing for patent losses and changes to the health care system in the United States. He joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving into key international roles for seven years - as president and general manager of Lilly's affiliate in China, one of the world's fastest-growing pharmaceutical markets. He previously served as general manager of Lilly Canada after roles there as director of pharmaceutical marketing and national sales director. He earned a bachelor's degree in business from Purdue University and an MBA from Indiana University. Prior to joining Lilly, he held positions with Hewlett-Packard Corp. and IBM.

Jeffrey Simmons

Fionnuala Walsh

Ms. Fionnuala M. Walsh Ph.D., is Senior Vice President - Global Quality of Eli Lilly And Co. Her presence on the company's senior governance committee is expected to further underscore Lilly's ongoing commitment to quality. She earned a bachelor's degree and doctoral degree in chemistry from University College Dublin. She joined Lilly's Kinsale, Ireland , manufacturing site in 1988 as a technical services chemist. After positions there, she moved into a role as global quality leader at the Lilly Corporate Center in Indianapolis in 2002. In January 2003 , she was named executive director of quality for U.S. drug product and Lilly Technology Center operations. In July 2005 , she was named vice president of global quality operations, and, in June 2007 , she was named senior vice president of global quality.

Alfonso Zulueta

Mr. Alfonso Zulueta is Senior Vice President and President - Emerging Markets business of Eli Lilly & Co. Zulueta received a bachelor's degree in economics from De La Salle University in the Philippines in 1982 and an MBA from the University of Virginia in 1987. In his 25 year career with Lilly, Zulueta has held several sales and marketing leadership positions in the United States before becoming general manager for the Philippines affiliate in 1995. He served as president of Asian operations prior to being promoted in 2008 to his current role as president and general manager of Lilly Japan, the company's second largest market and affiliate behind only the U.S.

Ellen Marram

Ms. Ellen R. Marram is Lead Independent Director of Eli Lilly and Company. She served as Acting Chairperson of the Board of the Company from May 13, 2013 to July 8, 2013. She is President, The Barnegat Group LLC. Ms. Marram began serving as the board's lead director in April 2012. Ms. Marram is the president of The Barnegat Group LLC, a firm that provides business advisory services. She was a managing director at North Castle Partners, LLC from 2000 to 2005 and served as an advisor to the firm from 2006 to 2010. From 1993 to 1998, Ms. Marram was president and chief executive officer of Pepsico's Tropicana and the Tropicana Beverage Group. From 1988 to 1993, she was president and chief executive officer of the Nabisco Biscuit Company, the operating unit of Nabisco, Inc.; from 1987 to 1988, she was president of Nabisco's grocery division; and from 1970 to 1986, she held a series of marketing positions at Nabisco/Standard Brands, Johnson & Johnson, and Lever Brothers. Ms. Marram is a member of the board of directors of Ford Motor Company and The New York Times Company, as well as several private companies. She previously served on the board of Cadbury plc. She also serves on the boards of Wellesley College, Institute for the Future, New York-Presbyterian Hospital, Lincoln Center Theater, and Families and Work Institute.

Ralph Alvarez

Mr. Ralph Alvarez is an Independent Director of Eli Lilly & Co. Mr. Alvarez is executive chairman of Skylark Co., Ltd., a restaurant operator in Japan, a position he has held since January 2013. Previously, Mr. Alvarez served as president and chief operating officer of McDonald's Corporation from August 2006 until his retirement in December 2009. He also served as president of McDonald's North America, with responsibility for all the McDonald's restaurants in the U.S. and Canada. Prior to that, he was president of McDonald's USA. Mr. Alvarez joined McDonald's in 1994 and held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald's USA and president of McDonald's Mexico. Prior to joining McDonald's, he held leadership positions at Burger King Corporation and Wendy's International, Inc. Mr. Alvarez serves on the board of directors of Skylark Co., Ltd., Lowe's Companies, Inc., and Dunkin' Brands Group, Inc. Mr. Alvarez also serves on the President's Council, the School of Business Administration Board of Overseers, and the International Advisory Board of the University of Miami. He was previously a member of the boards of McDonald's Corporation and KeyCorp.

Katherine Baicker

Dr. Professor Katherine Baicker, Ph.D., is an Independent Director of Eli Lilly and Co. She is Professor of Health Economics at the Harvard University School of Public Health, Department of Health Policy and Management; and Research Associate at the National Bureau of Economic Research Dr. Baicker has been a professor of health economics at the Department of Health Policy and Management, School of Public Health, since 2007. From 2005 to 2007, she served as a Senate-confirmed member of the Council of Economic Advisers. From 1998 to 2005, Dr. Baicker was assistant professor and associate professor of economics at Dartmouth College. In 2001 and 2002 she also served as an economist to the Council of Economic Advisers, Executive Office of the President, and in 2003 was a visiting assistant professor at the University of Chicago Harris School of Public Policy. Dr. Baicker is a commissioner of the Medicare Payment Advisory Commission and serves on the Panel of Health Advisers to the Congressional Budget Office. She is a member of the editorial boards of Health Affairs and the Journal of Health Economics, chair of the board of directors of AcademyHealth, editor of the Forum for Health Economics and Policy, and associate editor of the Journal of Economic Perspectives. She is an elected member of the Institute of Medicine.

Winfried Bischoff

Sir Winfried Franz Wilhelm Bischoff is an Independent Director of Eli Lilly & Co. Sir Winfried Bischoff has been chairman of the board of Lloyds Banking Group plc since September 2009. He served as chairman of Citigroup Inc. from December 2007 until February 2009 and as interim chief executive officer for a portion of 2007. He served as chairman of Citigroup Europe from 2000 to 2009. From 1995 to 2000, he was chairman of Schroders plc. He joined the Schroder Group in 1966 and held a number of positions there, including chairman of J. Henry Schroder & Co., and group chief executive of Schroders plc. He is also a director of The McGraw-Hill Companies, Inc. He previously served on the boards of Citigroup Inc., Prudential plc, Land Securities plc, and Akbank T.A.S. He is a globalist, with particular experience in European matters but with experience overseeing worldwide operations. He has corporate governance experience from his service on public company boards in the U.S., UK, and other European and Asian countries.

Michael Eskew

Mr. Michael L. Eskew is an Independent Director of Eli Lilly & Co. He is Former Chairman and Chief Executive Officer, United Parcel Service, Inc. Mr. Eskew served as chairman and chief executive officer of United Parcel Service, Inc., from January 2002 until December 2007. He has served on the UPS board of directors since 1998. Mr. Eskew began his UPS career in 1972 as an industrial engineering manager and held various positions of increasing responsibility, including time with UPS's operations in Germany and with UPS Airlines. In 1993, Mr. Eskew was named corporate vice president for industrial engineering. Two years later he became group vice president for engineering. In 1998, he was elected to the UPS board of directors. In 1999, Mr. Eskew was named executive vice president and a year later was given the additional title of vice chairman. He serves as chairman of the board of trustees of The Annie E. Casey Foundation. Mr. Eskew also serves on the boards of 3M Corporation and IBM Corporation.

J. Erik Fyrwald

Mr. J. Erik Fyrwald is an Independent Director of Eli Lilly & Co. He is President and Chief Executive Officer, Univar, Inc. J. Erik Fyrwald joined Univar Inc., a distributor of industrial and specialty chemicals and provider of related services, in May 2012 as its president and chief executive officer. In 2008, following a 27-year career at E.I. duPont de Nemours and Company (DuPont), he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with Ecolab Inc. Following the merger, Mr. Fyrwald served as president of Ecolab. From 2003 to 2008, Mr. Fyrwald served as group vice president of the agriculture and nutrition division at DuPont. From 2000 until 2003, he was vice president and general manager of DuPont's nutrition and health business. At DuPont, he held a broad variety of assignments in a number of divisions covering many industries. He has worked in several locations throughout North America and Asia. Mr. Fyrwald serves as a director of the Society of Chemical Industry, Amsted Industries, and the Chicago Public Education Fund, and he is a trustee of the Field Museum of Chicago.

Alfred Gilman

Dr. Alfred G. Gilman, M.D., Ph.D., is an Independent Director of Eli Lilly & Co. He is Regental Professor of Pharmacology Emeritus, University of Texas Southwestern Medical Center at Dallas Dr. Gilman is the regental professor of pharmacology emeritus at the University of Texas Southwestern Medical Center at Dallas. Dr. Gilman was on the faculty of the University of Virginia School of Medicine from 1971 to 1981 and was named a professor of pharmacology there in 1977. He previously served as executive vice president for academic affairs and provost of the University of Texas Southwestern Medical Center at Dallas, dean of the University of Texas Southwestern Medical School, and professor of pharmacology at the University of Texas Southwestern Medical Center. He held the Raymond and Ellen Willie Distinguished Chair of Molecular Neuropharmacology, the Nadine and Tom Craddick Distinguished Chair in Medical Science, and the Atticus James Gill, M.D., Chair in Medical Science at the university and was named a regental professor in 1995. Between 2009 and 2012, Dr. Gilman was the chief scientific officer of the Cancer Prevention and Research Institute of Texas. He is a director of Regeneron Pharmaceuticals, Inc. Dr. Gilman was a recipient of the Nobel Prize in Physiology or Medicine in 1994.

R. David Hoover

Mr. R. David Hoover is an Independent Director of Eli Lilly & Co. Mr. Hoover is chairman of Ball Corporation, which provides metal packaging for beverages, foods and household products, as well as aerospace and other technologies and services to commercial and governmental customers. Mr. Hoover joined Ball Corporation in 1970 and has held a variety of leadership roles throughout his career, including vice president and treasurer; executive vice president and chief financial officer; vice chairman, president, and chief operating officer; and chairman, president, and chief executive officer. He is a member of the boards of Ball Corporation, Energizer Holdings, Inc., and Steelcase, Inc. Mr. Hoover is also a director of Boulder Community Hospital, Children's Hospital Colorado, and a member of the Colorado Forum, and is a member and past chair of the board of trustees of DePauw University and on the Indiana University Kelley School of Business Dean's Council. Mr. Hoover previously served on the boards of Irwin Financial Corporation and Qwest International, Inc.

Karen Horn

Dr. Karen N. Horn, Ph.D., is an Independent Director of Eli Lilly & Co. She is Retired President, Private Client Services; Managing Director, Marsh, Inc. Ms. Horn served as president of private client services and managing director of Marsh, Inc., a global provider of risk and insurance services, from 1999 until her retirement in 2003. Prior to joining Marsh, she was senior managing director and head of international private banking at Bankers Trust Company, chairman and chief executive officer of Bank One, Cleveland, N.A., president of the Federal Reserve Bank of Cleveland, treasurer of Bell Telephone Company of Pennsylvania, and vice president of First National Bank of Boston. Ms. Horn serves as director of T. Rowe Price Mutual Funds, Simon Property Group, Inc., and Norfolk Southern Corporation. She previously served on the boards of Fannie Mae and Georgia-Pacific Corporation. Ms. Horn has been senior managing director of Brock Capital Group, a provider of financial advising and consulting services, since 2004.

William Kaelin

Dr. William G. Kaelin Jr., M.D., is Independent Director of Eli Lilly and Co. He is Professor, Department of Medicine and Associate Director, Basic Science; Dana-Farber/Harvard Cancer Center Dr. Kaelin, who is currently serving under interim election, joined the board in June 2012 and was referred to the directors and corporate governance committee by an incumbent independent director. Dr. Kaelin is a professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women's Hospital, Harvard Medical School, where he began his career as an independent investigator in 1992. He currently serves as associate director, Basic Science, for the Dana-Farber/Harvard Cancer Center. Dr. Kaelin is a prominent member of the medical research community and has received broad recognition for his work in oncology research, including the Canada Gairdner International Award and the Lefoulon-Delalande Prize from the Institute of France. Dr. Kaelin is a member of the Institute of Medicine, the National Academy of Sciences, and the Association of American Physicians.

Douglas Oberhelman

Mr. Douglas R. Oberhelman is an Independent Director of Eli Lilly & Co. He is Chairman and Chief Executive Officer, Caterpillar Inc. Mr. Oberhelman has been chairman of the board of Caterpillar Inc. since November 2010 and chief executive officer since July 2010. He previously served as vice chairman and chief executive officer-elect of Caterpillar. He joined Caterpillar in 1975 and has held a variety of positions, including senior finance representative based in South America for Caterpillar Americas Co., regional finance manager and district manager for the company's North American commercial division, and managing director and vice general manager for strategic planning at Caterpillar Japan Ltd. Mr. Oberhelman was elected a vice president in 1995, serving as Caterpillar's chief financial officer from 1995 to November 1998. In 1998, he became vice president with responsibility for the engine products division and he was elected a group president and member of Caterpillar's executive office in 2002. Mr. Oberhelman serves on the boards of Caterpillar, the Wetlands America Trust, and is chairman of the National Association of Manufacturers. He previously served on the board of Ameren Corporation. He is a member of the Executive Committee of the Business Roundtable and a member of the Business Council.

Franklyn Prendergast

Dr. Franklyn G. Prendergast, M.D., Ph.D., is an Independent Director of Eli Lilly & Co. He is Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School; and Director Emeritus, Mayo Clinic Center for Individualized Medicine Dr. Prendergast is the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics at Mayo Medical School and the director emeritus of the Mayo Clinic Center for Individualized Medicine. He is an emeritus member of the Mayo Clinic board of governors and board of trustees and has held several teaching positions at the Mayo Medical School since 1975. Dr. Prendergast is a prominent medical clinician, researcher, and academician. He has experience in senior-most administration at Mayo Clinic, a medical institution, and as director of its cancer center. He has special experience in two critical areas for Lilly—oncology and personalized medicine.

Marschall Runge

Dr. Marschall S. Runge, M.D., Ph.D., has been appointed as Independent Director of Eli Lilly and Company effective September 1, 2013. Dr. Runge is the Executive Dean for the School of Medicine at the University of North Carolina at Chapel Hill. In his role as Executive Dean for the UNC School of Medicine, Dr. Runge provides overall academic and clinical leadership for the School of Medicine and the UNC Health Care System. In addition to being the Chair of the Department of Medicine, Dr. Runge is also Principal Investigator and Director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill, where he has financial, human resource and strategic oversight responsibilities for the program. An honors graduate of Vanderbilt University with a B.A. in Biology and a Ph.D. in molecular biology, Dr. Runge earned his M.D. from the Johns Hopkins School of Medicine, where he was an intern and resident in internal medicine. He then completed a cardiology fellowship at Harvard's Massachusetts General Hospital and was a faculty member there prior to moving to Emory University as an Associate Professor of Medicine in 1989. Before joining the UNC faculty in 2000, Dr. Runge held the John Sealy Distinguished Centennial Chair in Internal Medicine and was Director of the Division of Cardiology and the Sealy Center for Molecular Cardiology at the University of Texas Medical Branch at Galveston. In addition to serving as a member of the Experimental Cardiovascular Sciences Study Section of the National Institutes of Health, Dr. Runge also has published over 150 peer-reviewed manuscripts.

Kathi Seifert

Ms. Kathi P. Seifert is an Independent Director of Eli Lilly & Co. She is Retired Executive Vice President, Kimberly-Clark Corporation Ms. Seifert served as executive vice president for Kimberly-Clark Corporation, a global consumer products company, until June 2004. She joined Kimberly-Clark in 1978 and served in several capacities in connection with both the domestic and international consumer-products businesses. Prior to joining Kimberly-Clark, Ms. Seifert held management positions at Procter & Gamble, Beatrice Foods, and Fort Howard Paper Company. She is chairman of Katapult, LLC, a provider of pro bono mentoring and consulting services to other nonprofits. Ms. Seifert serves on the boards of Supervalu Inc.; Revlon Consumer Products Corporation; Lexmark International, Inc.; Appleton Papers Inc.; Fox Cities Performing Arts Center; and the Community Foundation for the Fox Valley Region.

Jackson Tai

Mr. Jackson Pei Tai has been appointed as Independent Director of Eli Lilly and Company effective November 1, 2013. He serves as a non-executive director of The Bank of China Limited, Singapore Airlines, NYSE Euronext, MasterCard Incorporated, and Royal Philips NV. From 2002 to 2007, he was vice chairman and chief executive officer of both DBS Group Holdings and DBS Bank, one of the largest financial services groups in Asia. Tai joined DBS as Chief Financial Officer in July 1999 and was president and chief operating officer of DBS from January 2001 to June 2002. Prior to his appointment at DBS, Tai was an investment banker for 25 years with J.P. Morgan & Co. Incorporated. Among his assignments at J.P. Morgan, Tai was senior regional officer and head of investment banking for Asia Pacific, based in Tokyo; founder and global head of real estate investment banking, based in New York; senior regional officer and head of investment banking for the Western United States, based in San Francisco; and executive director of J.P. Morgan Securities' Japanese business, based in Tokyo. Tai serves as a trustee of Rensselaer Polytechnic Institute and a director of the Committee of 100. He is a member of the Harvard China Advisory Group and the Harvard Business School Asia-Pacific Advisory Board. He is also a director of privately-held Russell Reynolds Associates and Brookstone, Inc. Tai received his MBA in 1974 from Harvard University where he was a recipient of a Council on Graduate Medical Education fellowship. He graduated from Rensselaer Polytechnic Institute in 1972 with a Bachelors of Science degree in Management.
Search Stocks